In addition to linagliptin's cardioprotective effects mediated by reducing metabolic risk factors (eg hyperglycaemia and hyperlipidaemia), we found that linagliptin directly prevented DPP‐4‐mediated cleavage of titin, specifically in the N2Bus and PEVK regions, resulting in decreased cardiomyocyte Fpassive in vitro. Here, DPP4 is linked to hyperlipidemia.